Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Between Nov. 83 and Oct. 84 15 children under chemotherapy for malignant diseases, 2 relatives and 2 nurses developed hepatitis-B antigen seropositivity. Epidemiological studies gave evidence for non-parenteral spread of the infection. The course of the disease was usually asymptomatic or mild. Amongst the patients who developed hepatitis-B there was a considerable number of children who had presented with a recurrence of their malignant disease. Two characteristic cases of hepatitis B are presented showing the wide range of clinical manifestations of this disease in immunocompromised children with ALL.
 ...
PMID:[Hepatitis B infections in cytostatically treated children]. 345 37

Serum alpha-fetoprotein levels were measured serially by radioimmunoassay in 32 patients with acute viral hepatitis. With one exception, the levels were increased during the course of the illness. Raised concentrations of the protein occurred almost equally in patients with and without the hepatitis-B antigen. In the majority of patients the rise was modest but in seven levels were reached at which alpha-fetoprotein could be detected by immunodiffusion. Very high levels were more likely to occur in children. In eight patients the concentration increased as the serum glutamic pyruvic transaminase (SGPT) level, used as an index of hepatocyte damage, was returning to normal, a pattern which favoured increased synthesis of the protein during hepatocellular regeneration. In the remainder, the alpha-fetoprotein level paralleled that of SGPT, suggesting rather an acutephase reaction to liver injury.
 ...
PMID:Serum alpha-fetoprotein levels in acute viral hepatitis. 413 54

The ability of purified, heat-inactivated hepatitis-B antigen (HBAg) to stimulate sensitized lymphocytes in vitro was investigated with the lymphocyte stimulation test on lymphocytes from three groups of individuals. Stimulation was minimal in the lymphocytes of two out of 15 normal controls, whereas lymphocytes from nine out of 12 patients who had recovered from hepatitis B showed stimulation, as did lymphocytes from five out of 12 laboratory technicians who had been regularly exposed to HBAg but who had no history of hepatitis or signs of it in the previous two years. No differences were observed in the responses to phytohaemagglutinin of lymphocytes from persons in the three groups. HBAg and HBAg inactivated by heat were shown in immunodiffusion to be immunologically identical. Inactivated HBAg stimulated antibody production in guinea-pigs. These findings suggest that not only humoral but also cell-mediated immunity might be induced by vaccination with purified, heat-inactivated HBAg.
 ...
PMID:Specific lymphocyte stimulation by purified, heat-inactivated hepatitis-B antigen. 420 72

A long-term follow-up of 45 patients with chronic hepatitis and 41 with cirrhosis is reported. Hepatitis-B antigen (HBAg) was present in 19 (42%) of the chronic hepatitis patients and in 20 (49%) of those with cirrhosis. The clinical course and biochemical and histological findings in the HBAg-positive and the HBAg-negative cases were similar, suggesting that HBAg-positive chronic liver disease is not a distinct clinical entity. The presence of antigen and autoantibodies was not found to be mutually exclusive. In HBAg-positive cases antigen tended to persist for months and years. When no irreversible lesions exist disappearance of the antigen may be a sign that the liver disease will resolve.
 ...
PMID:Chronic liver disease and hepatitis-B antigen: a prospective study. 421 93

A solid-phase radioimmunoassay (Ausria-125) was compared to an immunoelectro-osmophoresis method in detecting hepatitis-B antigen (HBAg). The radioimmunoassay detected HBAg in approximately 230 times higher dilutions than the immunoelectroosmophoresis method. In cases of acute hepatitis HBAg could be detected for about 70% longer after the onset of jaundice using radioimmunoassay compared with immunoelectroosmophoresis. Of 138 patients with acute hepatitis, who were HBAg-negative by immunoelectroosmophoresis, 23 (17%) were positive by radioimmunoassay. The specificity of the positive results with this test was investigated by neutralization tests with human antiserum to HBAg.
 ...
PMID:Evaluation of a solid phase radioimmunoassay (Ausria-125) for the detection of hepatitis B antigen (Australia antigen) in two clinical materials. 485 88

The morphological similarities between B and non-A, non-B hepatitis viruses prompted the search for common antigenic determinants between the two agents. Major antigenic cross-reactivity was demonstrated by immunodiffusion between hepatitis B e/3 and the most common circulating antigen previously reported in the serum of patients with non-A, non-B hepatitis. Since it is the equivalent of an e antigen, this antigen will be hereafter referred to as non-A, non-B/e antigen. Screening with hepatitis B e/3 antigen or anti-hepatitis B e/3 by immunodiffusion may be used as an easy and efficient way to test for non-A, non-B hepatitis in the absence of specific reagents since it detected up to 91% of non-A, non-B antigen and 86% of anti-non-A, non-B/e. Antigenic cross-reactivity may be used to look for additional viruses belonging to the hepatitis B group.
 ...
PMID:Use of the cross-reactivity between hepatitis B and non-A, non-B viruses for the identification and detection of non-A, non-B 'e' antigen. 616 43

An autopsy case of pulmonary hypertension in a 29-year-old Japanese female with macronodular, posthepatic liver cirrhosis and hepatitis-B antigenemia was presented. No recognizable known cardio-pulmonary disease or portal thrombosis was obtained. Hepatitis-B antigen was demonstrated in the cirrhotic hepatocytes by a specific peroxidase antiperoxidase method. Characteristic pulmonary arterial changes including plexiform lesions with varying developmental stages were widely observed throughout the lungs. Complication of these two distinct disease processes seems to be rarely encountered in the literature. Discussion was focused on the possible interrelationship between the liver cirrhosis with hepatitis-B antigenemia and pulmonary hypertension. Proposed were presumptive underlying humoral, particularly immunological, abnormalities common to these diseases rather than mere incidental complications.
 ...
PMID:Pulmonary hypertension associated with liver cirrhosis and hepatitis-B antigenemia. 634 Feb 45

An antigen-antibody system has been identified by immunofluorescence in patients with non-A, non-B hepatitis. The non-A, non-B antigen was localized in the hepatocyte nuclei of liver biopsies from patients with acute post-transfusion or sporadic non-A, non-B hepatitis and in those from patients with chronic post-transfusion non-A, non-B hepatitis, the percentage of positive cells being most prominent in patients receiving immunosuppressive treatment. Absence of the antigen in normal livers and in livers from patients with type B hepatitis infection indicated its specific association with non-A, non-B infection. Antibody reacting with the nuclear antigen became detectable in serum during post-transfusion acute non-A, non-B hepatitis in 11 out of 15 cases; it was absent before transfusion. Six out of 12 cases of sporadic acute non-A, non-B hepatitis were also found to produce the antibody, which was repeatedly found to be absent during the acute phase in five patients with type A and in eight with type B hepatitis. The non-A, non-B antibody, mainly an IgM antibody, persisted in serum for prolonged periods of time after onset, both in patients showing biochemical resolution of their illness and in those who continued to have liver damage after the acute phase. Accordingly, eight out of nine patients with chronic non-A, non-B hepatitis were found positive for the antibody in serum, seven at the time the non-A, non-B antigen was detected in their liver. Thus this non-A, non-B associated antigen-antibody system shares remarkable similarities of behaviour with the "core" system of the hepatitis B virus.
 ...
PMID:Detection by immunofluorescence of an antigen-antibody system in patients with acute and chronic non-A, non-B hepatitis. 681 7

We conducted a randomized trial comparing expectant management versus immunotherapy with paternal leukocytes to improve obstetric outcome in women with unexplained recurrent abortion. Eligible for the study were women with unexplained recurrent abortion (three or more miscarriages and no live birth), negative findings of immunological screening and no inhibition of the mixed lymphocyte culture. These women were seen for the first time between October 1988 and March 1991 in a network of obstetric departments in Northern Italy. Subjects positive for HLA DR3 or with a partner positive for hepatitis virus B antigen were not eligible. A total of 44 women entered the study. Patients were randomly allocated to immunotherapy (22 women) or expectant management (22 women). Women allocated to immunotherapy were given 200 x 10(6) purified paternal lymphocytes before pregnancy. Median follow-up was 24 months (range 10-39) in the immunotherapy group and 25 months (range 11-38) in the expectant management group. Out of the 22 women randomized to immunotherapy, 16 became pregnant and the corresponding value was 14 in the expectant management group. Spontaneous abortion occurred in six out of the 16 pregnancies observed in the treated women. Among the 14 pregnancies observed in the expectant management group, two aborted and one late fetal death occurred. The cumulative proportions of women who became pregnant over 4 years were 37 and 45% in the immunotherapy and expectant management groups respectively; this difference was not significant. No adverse effect was observed in treated women.
 ...
PMID:Immunotherapy and recurrent abortion: a randomized clinical trial. 796 26

Blood collected by 11 Red Cross Regional Blood Centers were screened by the method of agar gel diffusion (AGD) for the presence of hepatitis-B antibody. Of the 185,134 units tested, 114 were found to be positive for HBAb by the Regional Centers and were forwarded to National Special Projects Laboratory for confirmation. Only five out of 114 samples revealed lines of identity with a control anti-HBAg when reacted with a pool of plasma positive for hepatitis-B antigen that was different from that which was provided to the Centers. Apparently, the precipitation reactions observed by the Centers were largely due to the antithrombin antibodies in the donors' sera reacting with the residual thrombin used by the manufacturer to convert HBAg positive plasma to serum. We conclude that the incidence of hepatitis-B antibody as measured by agar gel diffusion in the Red Cross Blood donor population was extremely low.
 ...
PMID:American National Red Cross experience with hepatitis-B antibody (HBAb or anti-HBAg) testing. 1273 88


<< Previous 1 2 3 4 Next >>